Regional Partnership Grants Reauthorization Act of 2024
Impact
By reauthorizing this program, HB 8890 is expected to provide critical support to families with children at risk of entering or re-entering the child welfare system due to substance use disorders. The bill mandates the use of evidence-based practices to improve outcomes for these families, thereby aligning state actions with federal standards. It also enhances existing grant programs to accommodate technical assistance and promote better integration of resources among state agencies, ultimately aiming for a holistic approach to family treatment services.
Summary
House Bill 8890, known as the Regional Partnership Grants Reauthorization Act of 2024, aims to extend the Regional Partnership Grant program for five additional years, specifically from 2024 to 2029. The bill modifies several provisions of the Social Security Act, focusing on enhancing funding avenues for states and localities. It clarifies the intent of these grants, directing them towards programs benefitting families affected by substance use disorder, particularly those involved with the child welfare system.
Contention
Discussions around HB 8890 highlight a focus on balancing the need for effective family-centered care while ensuring that funds are utilized efficiently. Key points of contention may arise regarding the allocation and management of these grants, particularly in how states implement these guidelines and measure their effectiveness. Critics may argue about the adequacy of grant amounts and the administrative overhead involved, as well as the importance of sustained funding amidst changing federal policies.
A bill for an act relating to controlled substances including the manufacture, delivery, or possession of a controlled substance including fentanyl; the manufacture of a controlled substance in the presence of a minor; conspiracy to manufacture for delivery or delivery or intent or conspiracy to deliver a controlled substance to a minor; receipt, provision, and administration of opioid antagonists, including by secondary distributors, providing for immunity; and providing penalties.(See HF 595.)
A bill for an act relating to controlled substances including the manufacture, delivery, or possession of a controlled substance including fentanyl; the manufacture of a controlled substance in the presence of a minor; conspiracy to manufacture for delivery or delivery or intent or conspiracy to deliver a controlled substance to a minor; receipt, provision, and administration of opioid antagonists, including by secondary distributors, providing for immunity; and providing penalties.(See SF 508.)
A bill for an act relating to controlled substances including the manufacture, delivery, or possession of a controlled substance including fentanyl; the manufacture of a controlled substance in the presence of a minor; conspiracy to manufacture for delivery or delivery or intent or conspiracy to deliver a controlled substance to a minor; receipt, provision, and administration of opioid antagonists, including by secondary distributors; providing for immunity; and providing penalties. (Formerly HSB 104.) Effective date: 07/01/2023.
A bill for an act relating to controlled substances including the manufacture, delivery, or possession of a controlled substance including fentanyl; the manufacture of a controlled substance in the presence of a minor; conspiracy to manufacture for delivery or delivery or intent or conspiracy to deliver a controlled substance to a minor; receipt, provision, and administration of opioid antagonists, including by secondary distributors; providing for immunity; and providing penalties.(Formerly SSB 1096.)